Anavar was the old U.S. brand name for the oral steroid oxandrolone, that was first produced in 1964 by the drug manufacturer Searle. It was designed as an extremely mild anabolic, that could even be safely used as a growth stimulant in children. One immediately thinks of the standard worry, "steroids including oxandrolone will stunt growth". But it is actually the excess estrogen produced by most steroids that is the culprit, just as it is the reason why women stop growing Anavar sooner and have a shorter average stature than men. Anavar will not aromatize, and therefore the anabolic effect of the Anavar compound can actually promote linear growth. Women usually tolerate this drug well at low doses, and at one time Anavar was prescribed for the treatment of osteoporosis. But the atmosphere surrounding steroids began to change rapidly in the 1980's, and prescriptions for Oxandrolone began to drop. Lagging sales probably led Searle to discontinue manufacture in 1989, and it had vanished from U.S. pharmacies until recently. Oxandrolone tablets are again available inside the U.S. by BTG, bearing the new brand name Oxandrin. BTG purchased rights to Anavar from Searle and is now manufactured for the new purpose of treating HIV/AIDS related wasting syndrome. Many welcomed this announcement, as Anavar had gained a very favorable reputation among athletes over the years.
){kind=link}